|
Cangene is hyper about hyperimmunes. The company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.
|
| | | Contact Information | |
Address: |
155 Innovation Drive
Winnipeg, Manitoba R3T 5Y3, Canada
| | Phone: | 204-275-4200 | | Fax: | 204-269-7003 |
|
| Financial
Highlights | | Fiscal Year End: | July | | Revenue (2008): | 162.20 M | | Revenue Growth (1 yr): | 86.90% | | Employees (2007): | 617 | | Employee Growth (1 yr): | 0.00% |
|
|
Key People
| | • |
Chairman:
Jacob M. (Jack) Kay
| | • |
President, CEO, and Director:
John Langstaff
| | • |
SVP Operations:
William Labossiere (Bill) Bees
|
|
|
